methyl (2R)-2-(4-aminophenyl)propanoate | 492445-74-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: methyl (2R)-2-(4-aminophenyl)propanoate
• CAS: 492445-74-6
• 化学式: C₁₀H₁₃NO₂
• 分子量: 179.219
• InChiKey: JSQLPIGKVBUMBF-SSDOTTSWSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  13
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  52.3
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  methyl (2R)-2-(4-aminophenyl)propanoate 、 sodium thiocyanide 在 硫酸 作用下， 以 甲苯 为溶剂， 反应 24.0h， 以49%的产率得到methyl (2R)-2-[4-(carbamothioylamino)phenyl]propanoate
  参考文献：
  名称：

  [EN] (R)-4-(HETEROARYL) PHENYLETHYL DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
  [FR] DÉRIVÉS DE (R)-4-(HÉTÉROARYL)PHÉNYLÉTHYLE ET COMPOSITIONS PHARMACEUTIQUES LES CONTENANT

  摘要：

  本发明涉及一类新型的(R)-4-(杂环)苯丙酸衍生物，其化学式为(I)，用于抑制由补体C5a分子引起的趋化活化。所述化合物在治疗依赖于补体C5a分子引起的中性粒细胞和单核细胞趋化活化的病理方面具有用处。具体而言，本发明的化合物在治疗自身免疫性溶血性贫血（AIHA）、银屑病、大疱性类天疱疮、类风湿性关节炎、溃疡性结肠炎、急性呼吸窘迫综合征、特发性纤维化、肾小球肾炎以及缺血再灌注所致损伤的预防和治疗方面具有用处。

  公开号：

  WO2009050258A1
• 作为产物：
  描述：

  methyl 2-(4-nitrophenyl)propanoate 在 盐酸 、 铁粉 作用下， 以 甲醇 、 水 为溶剂， 以76%的产率得到methyl (2R)-2-(4-aminophenyl)propanoate
  参考文献：
  名称：

  [EN] (R)-4-(HETEROARYL) PHENYLETHYL DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
  [FR] DÉRIVÉS DE (R)-4-(HÉTÉROARYL)PHÉNYLÉTHYLE ET COMPOSITIONS PHARMACEUTIQUES LES CONTENANT

  摘要：

  本发明涉及一类新型的(R)-4-(杂环)苯丙酸衍生物，其化学式为(I)，用于抑制由补体C5a分子引起的趋化活化。所述化合物在治疗依赖于补体C5a分子引起的中性粒细胞和单核细胞趋化活化的病理方面具有用处。具体而言，本发明的化合物在治疗自身免疫性溶血性贫血（AIHA）、银屑病、大疱性类天疱疮、类风湿性关节炎、溃疡性结肠炎、急性呼吸窘迫综合征、特发性纤维化、肾小球肾炎以及缺血再灌注所致损伤的预防和治疗方面具有用处。

  公开号：

  WO2009050258A1

文献信息

• Phenylacetamido-thiazole derivatives, process for the preparation and their use as antitumor agents
  申请人：——

  公开号：US20040235919A1

  公开（公告）日：2004-11-25

  Compounds represented by formula (I), as defined in the description, wherein R is a hydrogen atom or a methyl group and R1 is a group as defined in the specification, or a pharmaceutically acceptable salt thereof, are disclosed; the said compounds are useful in the treatment of cell proliferative disorders, e.g. cancer, associated with an altered cell cycle dependent kinase activity.

  公式(I)所代表的化合物，如描述中所定义，其中R是氢原子或甲基基团，R1是规范中定义的基团，或其药用盐，均已披露；所述化合物在治疗细胞增殖紊乱疾病（如癌症）方面具有用途，与细胞周期依赖性激酶活性异常有关。
• [EN] 2-ARYL-PROPIONIC ACIDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM<br/>[FR] ACIDES 2-ARYL-PROPIONIQUES ET COMPOSITIONS PHARMACEUTIQUES RENFERMANT CEUX-CI
  申请人：DOMPE SPA

  公开号：WO2003043625A1

  公开（公告）日：2003-05-30

  (R) and (S) 2-Aryl-propionic acids, and pharmaceutical compositions that contain them, are useful in inhibiting chemotactic activation of neutrophils (PMN leukocytes) induced by the interaction of Interleukin-8 (IL-8) with CXCR1 and CXCR2 membrane receptors. The acids are used for the prevention and treatment of pathologies deriving from said activation. In particular, the (R) enantiomers of said acids are lacking cyclo-oxygenase inhibition activity and are particularly useful in the treatment of neutrofil-dependent pathologies such as psoriasis, ulcerative colitis, melanoma, chronic obstructive pulmonary disease (COPD),bollous pemphigo, rheumatoid arthritis, idiopathic fibrosis, glomerulonephritis and in the prevention and treatment of damages caused by ischemia and reperfusion.

  (R)和(S) 2-芳基丙酸及含有它们的药物组合物，可用于抑制由白细胞介素-8（IL-8）与CXCR1和CXCR2膜受体相互作用引起的嗜中性粒细胞（PMN白细胞）的趋化活化。这些酸用于预防和治疗由该活化引起的病理。特别地，这些酸的(R)对映体缺乏环氧合酶抑制活性，特别适用于治疗依赖于中性粒细胞的病理，如银屑病，溃疡性结肠炎，黑色素瘤，慢性阻塞性肺疾病（COPD），天疱疮，类风湿性关节炎，特发性纤维化，肾小球肾炎以及缺血再灌注所致的损伤的预防和治疗。
• 2-Aryl-propionic acids and pharmaceutical compositions containing them
  申请人：Allegretti Marcello

  公开号：US20050038119A1

  公开（公告）日：2005-02-17

  (R) and (S) 2-Aryl-propionic acids, and pharmaceutical compositions that contain them, are useful in inhibiting chemotactic activation of neutrophils (PMN leukocytes) induced by the interaction of Interleukin-8 (IL-8) with CXCR1 and CXCR2 membrane receptors. The acids are used for the prevention and treatment of pathologies deriving from said activation. In particular, the (R) enantiomers of said acids are lacking cyclo-oxygenase inhibition activity and are particularly useful in the tratment of neutrofil-dependent pathologies such as psoriasis, ulcerative colitis, melanoma, chronic obstructive pulmonary disease (COPD), bollous pemphigo, rheumatoid arthritis, idiopathic fibrosis, glomerulonephritis and in the prevention and treatment of damages caused by ischemia and reperfusion.

  (R)和(S) 2-芳基-丙酸以及含有它们的制药组合物，在抑制由白细胞介素-8（IL-8）与CXCR1和CXCR2膜受体相互作用引起的嗜中性粒细胞（PMN白细胞）趋化激活方面非常有用。这些酸用于预防和治疗由该激活引起的病理状况。特别是，这些酸的(R)对映体缺乏环氧合酶抑制活性，特别适用于治疗依赖于嗜中性粒细胞的病理状况，如牛皮癣，溃疡性结肠炎，黑色素瘤，慢性阻塞性肺疾病（COPD），水疱性天疱疮，类风湿性关节炎，特发性纤维化，肾小球肾炎以及缺血再灌注所致的损伤的预防和治疗。
• (R)-4-(HETEROARYL) PHENYLETHYL DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
  申请人：Moriconi Alessio

  公开号：US20100249198A1

  公开（公告）日：2010-09-30

  The present invention relates to a novel class of (R)-4-(heteroaryl)phenylpropionic derivatives of formula (I), useful in the inhibition of the chemotactic activation induced by the fraction C5a of complement. Said compounds are useful in the treatment of pathologies depending on the chemotactic activation of neutrophils and monocytes induced by the fraction C5a of the complement. In particular, the compounds of the invention are useful in the treatment of autoimmune hemolytic anemia (AIHA), psoriasis, bullous pemphigoid, rheumatoid arthritis, ulcerative colitis, acute respiratory distress syndrome, idiopathic fibrosis, glomerulonephritis and in the prevention and treatment of injury caused by ischemia and reperfusion.

  本发明涉及一种新型的(R)-4-(杂环芳基)苯丙酸衍生物，化学式为(I)，其可用于抑制补体C5a分子诱导的趋化激活。该类化合物可用于治疗依赖于补体C5a分子诱导的中性粒细胞和单核细胞趋化激活的病理学。特别是，该发明的化合物可用于治疗自身免疫性溶血性贫血（AIHA）、银屑病、大疱性类天疱疮、类风湿性关节炎、溃疡性结肠炎、急性呼吸窘迫综合征、特发性纤维化、肾小球肾炎以及缺血再灌注引起的损伤的预防和治疗。
• (R)-4-(heteroaryl) phenylethyl derivatives and pharmaceutical compositions containing them
  申请人：Dompe S.p.A

  公开号：US08133911B2

  公开（公告）日：2012-03-13

  The present invention relates to a novel class of (R)-4-(heteroaryl)phenylpropionic derivatives of formula (I), useful in the inhibition of the chemotactic activation induced by the fraction C5a of complement. Said compounds are useful in the treatment of pathologies depending on the chemotactic activation of neutrophils and monocytes induced by the fraction C5a of the complement. In particular, the compounds of the invention are useful in the treatment of autoimmune hemolytic anemia (AIHA), psoriasis, bullous pemphigoid, rheumatoid arthritis, ulcerative colitis, acute respiratory distress syndrome, idiopathic fibrosis, glomerulonephritis and in the prevention and treatment of injury caused by ischemia and reperfusion.

  本发明涉及一类新型的(R)-4-(杂环芳基)苯丙酸衍生物，化学式为(I)，用于抑制补体C5a分子诱导的趋化活化。该类化合物在治疗由于补体C5a分子诱导的中性粒细胞和单核细胞趋化活化所引起的病理状况方面具有用途。特别地，本发明的化合物在治疗自身免疫性溶血性贫血（AIHA）、银屑病、大疱性类天疱疮、类风湿性关节炎、溃疡性结肠炎、急性呼吸窘迫综合症、特发性纤维化、肾小球肾炎以及缺血再灌注所致损伤的预防和治疗方面具有用途。